ZA855892B - Novel crystal modification - Google Patents

Novel crystal modification

Info

Publication number
ZA855892B
ZA855892B ZA855892A ZA855892A ZA855892B ZA 855892 B ZA855892 B ZA 855892B ZA 855892 A ZA855892 A ZA 855892A ZA 855892 A ZA855892 A ZA 855892A ZA 855892 B ZA855892 B ZA 855892B
Authority
ZA
South Africa
Prior art keywords
crystal modification
novel crystal
novel
modification
crystal
Prior art date
Application number
ZA855892A
Other languages
English (en)
Inventor
Peter Heinrich Stahl
Beat Schmitz
Original Assignee
Ciba Geigy Ag
Henkel Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4263070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA855892(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag, Henkel Kgaa filed Critical Ciba Geigy Ag
Publication of ZA855892B publication Critical patent/ZA855892B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA855892A 1984-08-06 1985-08-05 Novel crystal modification ZA855892B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH376884 1984-08-06

Publications (1)

Publication Number Publication Date
ZA855892B true ZA855892B (en) 1986-03-26

Family

ID=4263070

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA855892A ZA855892B (en) 1984-08-06 1985-08-05 Novel crystal modification

Country Status (26)

Country Link
US (2) US4639338A (fr)
EP (1) EP0177443B1 (fr)
JP (1) JPS6143196A (fr)
KR (1) KR940000817B1 (fr)
AR (4) AR240832A1 (fr)
AT (1) ATE47396T1 (fr)
AU (1) AU591066B2 (fr)
CA (1) CA1255694A (fr)
CY (1) CY1570A (fr)
DD (1) DD239597A5 (fr)
DE (1) DE3573783D1 (fr)
DK (1) DK167282B1 (fr)
DO (1) DOP1990004769A (fr)
ES (2) ES8701188A1 (fr)
FI (1) FI79712C (fr)
GR (1) GR851910B (fr)
HK (1) HK42591A (fr)
HU (1) HU193124B (fr)
IE (1) IE58077B1 (fr)
IL (1) IL75990A (fr)
MX (1) MX9203373A (fr)
NO (1) NO165401C (fr)
PH (1) PH24854A (fr)
PT (1) PT80916B (fr)
SG (1) SG91390G (fr)
ZA (1) ZA855892B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH664158A5 (fr) * 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.
ES2039237T3 (es) * 1986-04-24 1993-09-16 Fujisawa Pharmaceutical Co., Ltd. Procedimiento para preparar nuevos compuestos de acido difosfonico.
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
IT1222734B (it) * 1987-09-25 1990-09-12 Scalvo S P A Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina
PH26923A (en) * 1989-03-08 1992-12-03 Ciba Geigy N-substituted amino alkanediphosphonic acids
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (fr) 1992-04-15 1995-01-01 Ciba Geigy
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JP3266395B2 (ja) * 1993-11-24 2002-03-18 富士写真フイルム株式会社 有機薬品の晶析方法
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
DE69827079T2 (de) * 1997-07-15 2005-09-08 Gador S.A. Kristalline Form von N,N-dimethyl-3-amino-1-hydroxypropan-1,1-Diphosphonsäure Mononatriumsalz Monohydrat und ein Verfahren zu ihrer Herstellung
JP2002523514A (ja) 1998-08-27 2002-07-30 テバ ファーマシューティカル インダストリーズ リミティド アレンドロネートナトリウムの新規水和物型、その製造方法、及びその医薬組成物
EP1702924A3 (fr) * 1998-08-27 2007-07-18 Teva Pharmaceutical Industries Ltd Formes de type hydrate du sel de sodium de l'alendronate, procédés de préparation et compositions pharmaceutiques
EP0998932A1 (fr) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Forme d'administration pharmaceutique contenant des diphosphonates ou leurs sels et méthode pour la fabriquer
EP0998933A1 (fr) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Procédé pour la préparation de compositions pharmaucetiques contenant des diphosphonates pour administration orale
CA2353942A1 (fr) * 1998-12-10 2000-06-15 Edward C. Shinal Methode de preparation du pamidronate
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) * 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6315566B1 (en) 1999-05-18 2001-11-13 3M Innovative Properties Company Dental materials
US6143919A (en) * 1999-05-18 2000-11-07 3M Innovative Properties Company Polymerizable acidic compounds and methods of preparation
US6963008B2 (en) * 1999-07-19 2005-11-08 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
ES2153794B1 (es) * 1999-08-06 2001-10-16 Medichem Sa Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
KR100343232B1 (ko) * 1999-12-10 2002-07-10 김재윤 결정성 파미드론산 이나트륨염 수화물과 그의 제조방법
AU2001293473A1 (en) * 2000-09-18 2002-03-26 Mayne Pharma International Pty Ltd Diphosphonate solutions
US7560490B2 (en) * 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
EP1390044A4 (fr) 2001-05-02 2005-03-23 Sicor Inc Pamidronate disodique injectable
CA2347330C (fr) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Preparation injectable liquide de pamidronate disodique
ITMI20012751A1 (it) * 2001-12-21 2003-06-21 Lyogen Ltd Sale monosodico dell'acido pamidronico e procedimento per la sua preparazione
WO2003057136A2 (fr) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Forme posologique avec pastille noyau de principe actif enrobee dans un corps annulaire comprime de poudre ou de substance granulaire, et procede et outils pour la production de cette forme posologique
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
RU2315603C2 (ru) * 2002-12-20 2008-01-27 Ф.Хоффманн-Ля Рош Аг Композиция с высокой дозой ибандроната
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
EP1689759B1 (fr) * 2003-12-04 2016-07-13 Mustafa Nevzat Ilac Sanayii A.S. Procedes de production de pamidronate de disodium pur
PT1753395E (pt) 2004-05-24 2010-10-21 Warner Chilcott Co Llc Forma entérica sólida de dosagem oral de um bisfosfonato contendo um agente quelante
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2006039721A2 (fr) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Composes de bisphosphonate et methodes de traitement de maladies de resorption osseuse, de cancers, de douleurs osseuses, de troubles immunitaires et de maladies infectieuses
CA2646334A1 (fr) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Composes de biphosphonates et procedes
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
JP2011517313A (ja) 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
EP2473172B1 (fr) 2009-09-01 2015-04-08 Duke University Compositions de bisphosphonate et procédés de traitement d'une insuffisance cardiaque
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
MX2012012050A (es) 2010-04-16 2012-11-22 Novartis Ag Metodos y composiciones para mejorar la oseointegracion de implantes.
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
CA2987470A1 (fr) * 2012-05-14 2013-11-21 Antecip Bioventures Ii Llc Compositions comprenant de l'acide zoledronique ou des composes apparentes permettant de soulager une douleur inflammatoire et des etats associes
KR101995432B1 (ko) * 2016-10-13 2019-07-02 엘지전자 주식회사 공기조화기 및 그 제어방법
EP3553067A1 (fr) * 2018-04-10 2019-10-16 Abiogen Pharma S.p.A. Polymorphe de néridronate de sodium et son procédé de préparation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (de) * 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung von l-Hydroxy-S-amino-propan-ljl-diphosphonsäure
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
DE2553963A1 (de) * 1975-12-01 1977-06-08 Henkel & Cie Gmbh Pharmazeutische praeparate zur behandlung von stoerungen des calciumstoffwechsels
SE7612534L (sv) * 1975-12-01 1977-06-02 Henkel & Cie Gmbh Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning
SE409706B (sv) * 1976-05-21 1979-09-03 Astra Pharma Prod Forfarande for framstellning av n,n-dimetyl-3-(4-bromfenyl)-3-3(3-pyridyl)-allylamin dihydroklorid monohydrat
DE2702631A1 (de) * 1977-01-22 1978-07-27 Henkel Kgaa Verfahren zur herstellung von 1-hydroxy-3-amino-propan-1,1-diphosphonsaeuren
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) * 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
CH664158A5 (fr) * 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
JPH058717B2 (fr) 1993-02-02
ATE47396T1 (de) 1989-11-15
DE3573783D1 (en) 1989-11-23
HU193124B (en) 1987-08-28
IL75990A (en) 1989-07-31
ES555602A0 (es) 1987-07-01
US4639338A (en) 1987-01-27
EP0177443B1 (fr) 1989-10-18
NO165401B (no) 1990-10-29
PH24854A (en) 1990-12-26
HK42591A (en) 1991-06-07
FI79712B (fi) 1989-10-31
FI79712C (fi) 1990-02-12
PT80916A (en) 1985-09-01
AR244698A1 (es) 1993-11-30
NO165401C (no) 1991-02-06
AU4577785A (en) 1986-02-13
AR244697A1 (es) 1993-11-30
DOP1990004769A (es) 1999-08-19
KR860001821A (ko) 1986-03-22
EP0177443A1 (fr) 1986-04-09
CY1570A (en) 1991-12-20
SG91390G (en) 1991-01-18
HUT38361A (en) 1986-05-28
MX9203373A (es) 1992-09-01
ES545899A0 (es) 1986-11-16
KR940000817B1 (ko) 1994-02-02
ES8701188A1 (es) 1986-11-16
DK355485A (da) 1986-02-07
ES8706707A1 (es) 1987-07-01
AU591066B2 (en) 1989-11-30
DK355485D0 (da) 1985-08-05
DD239597A5 (de) 1986-10-01
AR244696A1 (es) 1993-11-30
CA1255694A (fr) 1989-06-13
US4711880A (en) 1987-12-08
DK167282B1 (da) 1993-10-04
AR240832A2 (es) 1991-02-28
IE851931L (en) 1986-02-06
NO853087L (no) 1986-02-07
FI852986A0 (fi) 1985-08-02
FI852986L (fi) 1986-02-07
GR851910B (fr) 1985-12-03
PT80916B (pt) 1987-12-30
AR240832A1 (es) 1991-02-28
JPS6143196A (ja) 1986-03-01
IE58077B1 (en) 1993-06-30

Similar Documents

Publication Publication Date Title
ZA855892B (en) Novel crystal modification
GB8507346D0 (en) Watch
EP0181601B1 (en) Liquid-crystal material
ZA855092B (en) Novel isoindolinyl-alkyl-piperazines
SG32390G (en) Novel 8a-acylaminoergolines
GB2162663B (en) Timepiece
GB2202989B (en) Crystal resonnator
EP0191269A3 (en) Novel homopropargylamines
GB2154020B (en) Display arrangement
CS515984A1 (en) Anesteziologicky okruh so spaetnym vdychovanim so vstrekovacom prchavych anestetik
ZA852440B (en) Novel substituted-aminohydroxypropoxy-thiadiazoles
GB8609480D0 (en) Single crystal
GB2153700B (en) Crystal growth
GB2211188B (en) New crystal form
ZA858971B (en) Novel homopropargylamines
GB8423553D0 (en) Clocks
GB2165683B (en) Display
KR870001200Y1 (en) Watch
GB8402707D0 (en) Watches
GB8413737D0 (en) Watches
GB8411569D0 (en) Sound-to-digital display
BG38693A1 (en) Glass crystal material
BG38694A1 (en) Glass crystal material
GB8424114D0 (en) Single crystal pulling
GB8429827D0 (en) Crucibles